

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE THREE MONTHS ENDED 31 MARCH 2024

On 11 April 2024, Dong-E-E-Jiao released its results estimate for the three months ended 31 March 2024.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 11 April 2024, Dong-E-E-Jiao released its results estimate for the three months ended 31 March 2024, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the three months ended 31 March 2024 is estimated to range from approximately RMB334 million to RMB357 million (as compared to the same period last year of approximately RMB230.3355 million), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB309 million to RMB332 million (as compared to the same period last year of approximately RMB212.3044 million), and basic earnings per share is estimated to range from approximately RMB0.52 per share to approximately RMB0.55 per share (as compared to the same period last year of approximately RMB0.3577 per share) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

In 2024, Dong-E-E-Jiao focuses closely on the development theme of “growth and quality” and deepens the implementation of “reshaping values, businesses, organisation and ethos.” It firmly establishes the leading position of the “Zi Bu Guo Bao Dong-E-E-Jiao” brand, infuses the brand with warmth, consolidates its brand status, and continues to drive brand rejuvenation and upgrading. It comprehensively establishes a dual growth model of pharmaceuticals and health consumer products, based on digital marketing and integrated marketing, constructs a strong brand barrier, and continues to strengthen its leading role in the value chain of E-Jiao block, build a diversified portfolio of compound E-Jiao paste products, and expand the “Taohuaji” as the leading brand of instant beauty and nourishment. Furthermore, it further clarifies the positioning of the “Royal Weichang 1619” men’s nourishment brand, delivers brand value in a multi-dimensional manner, and promotes incremental sales; and systematically plans the layout of its research and development system with “one center” and “three highlands”, drives business growth through technological innovation, and steadily improves operational performance.

Dong-E-E-Jiao will continue to adhere to a consumer-centric approach, deepen the dual growth model, continuously enhance the recognition of the “Zi Bu Guo Bao Dong-E-E-Jiao” brand, solidify and expand the foundation business, actively explore potential products, coordinate the cultivation of extension varieties, accelerate the construction of the research and development innovation system with “one center” and “three highlands”, gather new and high-quality productive forces, strive to maintain a steady and positive development in business operations, continuously improve quality, and become the most trusted leader in nourishment and health for the general public.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the quarterly report for the three months ended 31 March 2024 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

For further details of the Dong-E-E-Jiao quarterly financial information, please refer to the quarterly report for the three months ended 31 March 2024 to be published by Dong-E-E-Jiao on the website of the Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 12 April 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.